Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 12, 2002, Pages 1051-1057

  Garcia de Olalla P ^a,b   Martinez Gonzalez M A ^c   Cayla J A ^a,b   Jansa J M ^a   Iglesias, B ^a   Guerrero, R ^d   Marco, A ^e   Gatell, J M ^d   Ocana I ^b,f   Alguero C ^g   Vidal, R ^g   Lopez Colomes J L ^h   Barrio, J L ⁱ   Soriano, E ^f   Clotet, B ^j   Corominas, M ^d   Podzamczer, D ^d   Botia, A M ^a   Diez E ^a   Galdos H ^a   Panella H ^a   Plasencia A ^a   Brugal, M T ^a   more..

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Department of Justice ^*

^e Medical Service   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

Cox model; Directly observed therapy; HIV infection; Survival; Tuberculin skin test

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SPAIN; SURVIVAL RATE; TUBERCULIN TEST;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; COHORT STUDIES; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUBERCULOSIS;

EID: 0036929180     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Zumla A, Malon P, Henderson J, Grange J M. Impact of HIV infection on tuberculosis. Postgrad Med J 2000; 76: 259-268.
2. Ellner J. Tuberculosis in the time of AIDS. Chest 1990; 98: 1051-1052.
3. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001; 3: 225-232.
4. European Centre for the Epidemiological Monitoring of AIDS. HIV-AIDS Surveillance in Europe: Quarterly Report 65. Paris, 2001. (http://www.eurohiv.org/AidsSurv/rapport_65/).
5. Centers for Disease Control. Revision of the CDC surveillance. Case definition for acquired immunodeficiency syndrome. MMWR CDC Surveill Summ 1987; 36: 1s-15s.
6. Centro Nacional de Epidemiología. Registro Nacional de SIDA. Situación a 30 de Junio de 2001. Instituto de Salud Carlos III. Madrid: Ministerio de Sanidad y Consumo, 2001. (http://193.146.50.130/).
7. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341: 441.
8. Caylà J A, Galdós H, Jansà J M, Garcia de Olalla P, Brugal M T, Pañella H. Evolución de la tuberculosis en Barcelona (1987-1995). Influencia del virus de la inmunodeficiencia humana y de las medidas de control. Med Clin (Barc) 1998; 111: 608-615.
9. Garcia de Olalla P, Caylà J A, Brugal M T, Galdós H, Jansà J M, Clos R. Evolución de la mortalidad y supervivencia del sida en Barcelona. Med Clin (Barc) 1999; 113: 169-170.
10. Grupo de Trabajo sobre Tuberculosis. Consenso nacional para el control de la tuberculosis en España. Med Clin (Barc) 1992; 98: 24-31.
11. Caylà J A, Artazcoz L, Iglesias B, Jansà J M, Plasència A. Epidemiologia del SIDA en Barcelona (1981-1991) (II). Estudio de mortalidad y de supervivencia. Med Clin (Barc) 1994; 102: 129-135.
12. Hanson D L, Horsburg C R, Farm S I, Havlik J A, Thompson S E III. Survival prognosis of HIV-infected patients. J Acq Imm Def Syn 1993; 6: 624-629.
13. Lee E T. Statistical Methods for Survival Data Analysis. New York, NY: John Wiley & Sons, Inc., 1992.
14. Collet D. Modelling Survival Data in Medical Research. Texts in Statistical Science. London: Chapman & Hall, 1994.
15. Hosmer D W, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York, NY: Wiley, 1999.
16. Greenland S, Pearl J, Robins J M. Causal diagrams for epidemiologic research. Epidemiology 1999; 10: 37-48.
17. Borgdorff M W, Floyd K, Broekmans J E Interventions to reduce tuberculosis mortality and transmission in low-and middle-income countries. Bull World Health Organ 2002; 80: 217-227.
18. Chaulk C P, Kazandjian V A. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279: 943-948.
19. Alwood K, Keruly J, Moore-Rice K, Stanon D L, Chaulk C P, Chaisson R E. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994; 8: 1103-1108.
20. Wohl A R, Lu S, Rollins J N, Simon P A, Grosser S, Kerndt P R. Comparison of AIDS progression and survival in persons with pulmonary versus extra-pulmonary tuberculosis in Los Angeles. AIDS Patient Care STDS 2001; 15: 463-471.
21. Slutsker L, Castro K G, Ward J W, Dooley S W Jr. Epidemiology of extra-pulmonary tuberculosis among persons with AIDS in the United States. Clin Infect Dis 1993; 16: 513-518.
22. Richter C, Koelemay M J, Swai A B, Perenboom R, Mwakyusa D H, Oosting J. Predictive markers of survival in HIV-seropositive and HIV-seronegative Tanzanian patients with extra-pulmonary tuberculosis. Int J Tuberc Lung Dis 1995; 76: 510-517.
23. Martin V, Guerra J M, Cayla J A, Rodríguez J C, Blanco M D, Alcoba M. Incidence of tuberculosis and the importance of treatment of latent tuberculosis infection in a Spanish prison population. Int J Tuberc Lung Dis 2001; 10: 926-932.
24. Havlir D V, Barnes P F. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340: 367-373.
25. Walker A M. Confounding by indication. Epidemiology 1996; 7: 335-336.
26. Hogg R S, Yip B, Chan K J, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568-2577.
27. Lee L M, Karon J M, Selik R, Neal J J, Fleming P L. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001; 285: 1308-1315.
28. Volmink J, Garner P. Directly observed therapy for treating tuberculosis (Cochrane Review). Cochrane Database Syst Rev 2001; 4: CD003343.
29. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet 2000; 355: 1345-1350.
30. Shafer R W, Kim D S, Weiss J P, Quale J M. Extra-pulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore) 1991; 70: 384-397.